Pantomicina (Erythromycin Ethylsuccinate)

Erythromycin ethylsuccinate, the active ingredient in Pantomicina, is a macrolide antibiotic presented as an oral dosage form for oral use. It treats a range of bacterial infections in both adult and pediatric patients as directed by a healthcare professional.

GNH USA supplies Pantomicina as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantomicina, a macrolide antibiotic, is employed to manage bacterial infections affecting various organ systems.

- Respiratory tract infections: reduces bacterial load and improves cough, sputum production and fever. - Skin and soft‑tissue infections: treats staphylococcal and streptococcal cellulitis, impetigo and wound infections. - Sexually transmitted infections (e.g., chlamydia): eradicates the causative organism and resolves genital symptoms.

Pantomicina may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Vomiting: occasional expulsion of stomach contents. - Diarrhea: loose stools, sometimes watery. - Abdominal pain: cramping or discomfort. - Taste disturbance: altered or metallic taste. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Hepatotoxicity: signs of liver injury such as jaundice. - Severe allergic reactions: rash, swelling, anaphylaxis. - QT prolongation: risk of cardiac arrhythmias. - Clostridioides difficile‑associated diarrhea: severe colitis. - Stevens‑Johnson syndrome: serious skin and mucous membrane disorder. - Hemolytic anemia: destruction of red blood cells.

Before prescribing Pantomicina, clinicians should evaluate patient‑specific factors and monitor for potential complications.

- Assess renal and hepatic function: adjust therapy if impairment is present. - Monitor for allergic reactions: discontinue if severe hypersensitivity occurs. - Avoid in patients with known QT prolongation: increased risk of arrhythmia. - Use with caution in pregnancy: limited safety data, weigh benefits against risks. - Avoid concomitant use with other QT‑prolonging drugs: heightened cardiac risk. - Store at ambient temperature below 25°C: keep in the original package, protect from moisture.

Pantomicina can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Cisapride: risk of serious cardiac events. - Pimozide: increased plasma concentrations leading to toxicity. - Ergot alkaloids: potential for ergotism.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Theophylline: possible increase in serum levels, watch for toxicity. - Statins (e.g., simvastatin): may raise risk of myopathy, consider dose adjustment.